Drugs / TT Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02545868 | Oct 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02545868 ↗ |
| Modality | Vaccine | “The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection” NCT02545868 ↗ |
| Route | Intramuscular | “IM injection” NCT02545868 ↗ |